A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
Public ClinicalTrials.gov record NCT05556265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
Study identification
- NCT ID
- NCT05556265
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- Deucravacitinib Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2022
- Primary completion
- Jan 5, 2024
- Completion
- May 15, 2024
- Last update posted
- May 30, 2025
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0016 | Santa Monica | California | 90404-2120 | — |
| Local Institution - 0036 | New Haven | Connecticut | 06510 | — |
| Local Institution - 0018 | Tampa | Florida | 33624-2038 | — |
| Local Institution - 0023 | Clinton Township | Michigan | 48038-1137 | — |
| Local Institution - 0024 | New York | New York | 10029-6501 | — |
| Local Institution - 0019 | Chapel Hill | North Carolina | 27516-4061 | — |
| Local Institution - 0011 | Portland | Oregon | 97201-5134 | — |
| Local Institution - 0032 | Pittsburgh | Pennsylvania | 15213-3403 | — |
| Local Institution - 0012 | Austin | Texas | 78759 | — |
| Local Institution - 0013 | Houston | Texas | 77004-8098 | — |
| Local Institution - 0014 | San Antonio | Texas | 78213-2250 | — |
| Local Institution - 0017 | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05556265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05556265 live on ClinicalTrials.gov.